323 related articles for article (PubMed ID: 28795303)
1. The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients.
Guler OC; Engels B; Onal C; Everaert H; Van den Begin R; Gevaert T; de Ridder M
Clin Transl Oncol; 2018 Apr; 20(4):484-490. PubMed ID: 28795303
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Progression After
Soldatov A; von Klot CAJ; Walacides D; Derlin T; Bengel FM; Ross TL; Wester HJ; Derlin K; Kuczyk MA; Christiansen H; Henkenberens C
Int J Radiat Oncol Biol Phys; 2019 Jan; 103(1):95-104. PubMed ID: 30201438
[TBL] [Abstract][Full Text] [Related]
3. (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.
Henkenberens C; von Klot CA; Ross TL; Bengel FM; Wester HJ; Merseburger AS; Vogel-Claussen J; Christiansen H; Derlin T
Strahlenther Onkol; 2016 Jul; 192(7):431-9. PubMed ID: 27272755
[TBL] [Abstract][Full Text] [Related]
4. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
5.
Artigas C; Flamen P; Charlier F; Levillain H; Wimana Z; Diamand R; Albisinni S; Gil T; Velthoven RV; Peltier A; Gestel DV; Roumeguere T; Otte FX
World J Urol; 2019 Aug; 37(8):1535-1542. PubMed ID: 30824985
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
Kalinauskaite G; Senger C; Kluge A; Furth C; Kufeld M; Tinhofer I; Budach V; Beck M; Hochreiter A; Grün A; Stromberger C
PLoS One; 2020; 15(10):e0240892. PubMed ID: 33085712
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9.
Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
[No Abstract] [Full Text] [Related]
10. Treatment outcomes of metastasis-directed treatment using
Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
[TBL] [Abstract][Full Text] [Related]
11.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
12. Detection Efficacy of Hybrid
Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
[TBL] [Abstract][Full Text] [Related]
13. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
14. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
Onal C; Ozyigit G; Akgun Z; Atalar B; Igdem S; Oymak E; Agaoglu F; Selek U; Guler OC; Hurmuz P; Mustafayev TZ; Akyol F
Clin Nucl Med; 2021 Jun; 46(6):465-470. PubMed ID: 33661210
[TBL] [Abstract][Full Text] [Related]
15. Potential Impact of
Calais J; Kishan AU; Cao M; Fendler WP; Eiber M; Herrmann K; Ceci F; Reiter RE; Rettig MB; Hegde JV; Shaverdian N; King CR; Steinberg ML; Czernin J; Nickols NG
J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
[TBL] [Abstract][Full Text] [Related]
16. Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [
Berliner C; Tienken M; Frenzel T; Kobayashi Y; Helberg A; Kirchner U; Klutmann S; Beyersdorff D; Budäus L; Wester HJ; Mester J; Bannas P
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):670-677. PubMed ID: 27896369
[TBL] [Abstract][Full Text] [Related]
17. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
18. PSMA-PET guided dose-escalated volumetric arc therapy (VMAT) for newly diagnosed lymph node positive prostate cancer: Efficacy and toxicity outcomes at two years.
Shakespeare TP; Eggert E; Wood M; Westhuyzen J; Turnbull K; Rutherford N; Aherne N
Radiother Oncol; 2019 Dec; 141():188-191. PubMed ID: 31668514
[TBL] [Abstract][Full Text] [Related]
19. Integration of 68Ga-PSMA-PET/CT in Radiotherapy Planning for Prostate Cancer Patients.
Onal C; Torun N; Akyol F; Guler OC; Hurmuz P; Yildirim BA; Cağlar M; Reyhan M; Ozyigit G
Clin Nucl Med; 2019 Sep; 44(9):e510-e516. PubMed ID: 31283600
[TBL] [Abstract][Full Text] [Related]
20. Comparison of
Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
